Mersana Therapeutics to Host Conference Call Announcing First Quarter 2021 Financial Results and Business Updates

Rhea-AI Summary

Mersana Therapeutics (NASDAQ:MRSN) will hold a conference call on May 10, 2021, at 4:30 p.m. ET to discuss its Q1 2021 financial results and offer business updates. The call can be accessed by dialing 877-303-9226 domestically or 409-981-0870 internationally with the Conference ID 5046849. Mersana focuses on developing antibody-drug conjugates (ADCs) for cancer treatment, with its leading candidate, upifitamab rilsodotin, undergoing pivotal studies in ovarian and lung cancers, supported by their innovative ADC platforms.

Positive

• Focus on developing innovative ADCs targeting high unmet medical needs in cancer treatment.
• Ongoing clinical studies for lead product candidate, upifitamab rilsodotin, in platinum-resistant ovarian cancer and NSCLC.

Negative

• None.

CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Monday, May 10, 2021 at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2021 and provide business updates.  

To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 5046849. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy, in patients with platinum-resistant ovarian cancer as well as in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

Contact:

Investor & Media Contact
Sarah Carmody, 617-844-8577
scarmody@mersana.com

FAQ

What is the date of Mersana Therapeutics' Q1 2021 earnings call?

Mersana Therapeutics will host its Q1 2021 earnings call on May 10, 2021.

How can I access Mersana Therapeutics' conference call?

You can access the conference call by calling 877-303-9226 domestically or 409-981-0870 internationally, using Conference ID 5046849.

What is the focus of Mersana Therapeutics?

Mersana Therapeutics focuses on discovering and developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs.

What is Mersana's lead product candidate?

Mersana's lead product candidate is upifitamab rilsodotin, targeting NaPi2b in patients with platinum-resistant ovarian cancer.